

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/VDA31C057DE9EN.html>

Date: March 2022

Pages: 52

Price: US\$ 3,500.00 (Single User License)

ID: VDA31C057DE9EN

Abstracts

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The latest report Vascular Endothelial Growth Factor B - Drugs In Development, 2022, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1). The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 1 respectively. Report covers products from therapy areas Oncology, Ophthalmology and Metabolic Disorders which include indications Metastatic Colorectal Cancer, Colorectal Cancer, Diabetic Macular Edema, Diabetic Nephropathy, Lipid Disorders, Macular Degeneration, Macular

Edema, Non-Proliferative Diabetic Retinopathy (NPDR), Retinopathy, Solid Tumor, Uveal Melanoma and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects

The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies

Involved in Therapeutics Development

Alvotech ehf

CSL Ltd

GlycoNex Inc

Luye Pharma Group Ltd

Mabwell Shanghai Bioscience Co Ltd

Panolos Bioscience

Prestige BioPharma Ltd

Regeneron Pharmaceuticals Inc

Rophibio Inc

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

CSL-346 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PB-101 - Drug Profile

Product Description

Mechanism Of Action

ziv-afibercept - Drug Profile

Product Description

Mechanism Of Action

History of Events

ziv-afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones

Featured News & Press Releases

Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease

Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia

Mar 24, 2014: NICE rejects life-extending bowel cancer drug two weeks after Scottish approval

Sep 15, 2013: Approved cancer drug potentially could help treat diabetes, researchers find

Jun 20, 2013: NICE Turns Down Sanofi's Zaltrap For Treatment Of Metastatic Colorectal Cancer

Feb 05, 2013: Sanofi And Regeneron Pharma Receive EU Approval For Zaltrap For Patients With Previously Treated Metastatic Colorectal Cancer

Nov 16, 2012: Sanofi And Regeneron Pharma Announce CHMP Positive Opinion For Zaltrap For Previously Treated Metastatic Colorectal Cancer

Nov 08, 2012: Sanofi Offers Discount On Cancer Drug Zaltrap

Oct 08, 2012: Sanofi Announces Publication Of Phase III Results Of Zaltrap Study In Previously Treated Metastatic Colorectal Cancer Patients In Journal Of Clinical Oncology

Sep 07, 2012: Georgia Health Clinician Studies Zaltrap's Ability To Prolongs Survival In Patients With Metastatic Colon Cancer

Aug 03, 2012: FDA Approves ZALTRAP After Priority Review For Previously Treated Metastatic Colorectal Cancer

May 16, 2012: Sanofi To Present Data On Zaltrap At American Society Of Clinical Oncology Annual Meeting

Apr 05, 2012: Sanofi And Regeneron Announce ZALTRAP Phase III Study In Prostate Cancer Did Not Meet Primary Endpoint

Apr 05, 2012: Sanofi And Regeneron Receive FDA Priority Review For ZALTRAP Combination Chemotherapy

Sep 23, 2011: Regeneron Announces ZALTRAP Clinical Presentation At EMCC, Sweden

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Alvotech ehf, 2022

Pipeline by CSL Ltd, 2022

Pipeline by GlycoNex Inc, 2022

Pipeline by Luye Pharma Group Ltd, 2022

Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022

Pipeline by Panolos Bioscience, 2022

Pipeline by Prestige BioPharma Ltd, 2022

Pipeline by Regeneron Pharmaceuticals Inc, 2022

Pipeline by Rophibio Inc, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/VDA31C057DE9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VDA31C057DE9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970